Insulin glargine

Limits on what this shows

• Key negative/null findings: None reported in this source; all measured parameters moved in the coupling-improved direction.
• At-risk subgroups: None identified; this is a basic-science finding in cultured cells, not a clinical population.
• Counter-evidence: The insulin used was standard recombinant/human insulin in cell culture, not insulin glargine; glargine's altered receptor-binding kinetics and subcutaneous-depot pharmacokinetics were not tested, so direct extrapolation to glargine carries genuine uncertainty.

Regulatory status

Not addressed in labeling.

Population evidence

In vitro study, rat L6 myoblasts/myotubes and primary human skeletal-muscle myotubes from vastus lateralis biopsies, exposed to insulin 10–100 nM for 20 minutes and assessed by extracellular-flux (Seahorse XF24) respirometry (Nisr RB, Affourtit C. Biochim Biophys Acta 2014;1837(2):270–276). Coupling efficiency rose from roughly 80% to roughly 85% in L6 cells (p<0.01), with proportionally larger improvement in human cells; respiratory control ratio rose from 9–10 to about 12 in L6 cells (p<0.05). [11]

Mechanism

Named. Insulin acutely decreases mitochondrial proton leak, increasing the fraction of respiration coupled to ATP synthesis. [11]

Counter-evidence held on record

This is a protective, not a burden, signal at the class level. No clinical action is implied for glargine users specifically.

Limits on what this shows

• Key negative/null findings: Catalase and glutathione peroxidase activity fell alongside the oxidative-marker improvements, a mixed antioxidant-enzyme picture the authors describe as showing antioxidant protection improving "in a less degree" than oxidative-marker reduction. [8]
• At-risk subgroups: None identified as harmed; this is a population-level finding in patients starting or intensifying insulin analogue therapy.
• Counter-evidence: The study combined insulin aspart (rapid-acting, mealtime) with insulin glargine (basal); no arm isolates glargine's independent contribution, and the pre/post design cannot rule out confounding by simultaneous improvements in diet, self-monitoring, or glycemic control itself.

Regulatory status

Not addressed in labeling.

Population evidence

Prospective before/after study, 49 type 1 diabetes patients on intensive insulin analogue therapy (aspart plus glargine) for 6 months, compared with 42 control blood donors (Radenkovic et al., Acta Endocrinologica (Bucharest) 2023;19(4):463–470). After 6 months: malondialdehyde (p<0.001), xanthine oxidase (p<0.01), and nitrates/nitrites (p<0.05) all decreased; catalase and glutathione peroxidase decreased (p<0.001, p<0.01) while superoxide dismutase increased substantially (p<0.001). [8]

Mechanism

Not fully elucidated by the study authors; interpreted as improved glycemic control reducing hyperglycemia-driven oxidative stress rather than a direct antioxidant action of the insulin molecules themselves. [8]

Counter-evidence held on record

This entry exists to rebut an oxidative-stress-harm concern, not to support antioxidant-dosing recommendations.

Limits on what this shows

• Key negative/null findings: A targeted Crossref bibliographic search for human studies of exogenous insulin therapy and serum/tissue copper or related trace-element status returned no relevant results, underscoring how thin human trace-mineral/insulin data are outside this one diabetic-rat model.
• At-risk subgroups: None established in humans; the rat model used markedly supraphysiologic insulin dosing relative to typical human basal-glargine regimens.
• Counter-evidence: Neither cited study used insulin glargine; both are class-level/mechanistic (Tier C), and the rat dosing (12–16 U/kg twice daily) is far above human basal insulin exposure, limiting extrapolation.

Regulatory status

Not addressed in labeling.

Population evidence

Streptozotocin-induced diabetic rat models (type 1- and type 2-analogue) plus HepG2 hepatocyte cultures: subcutaneous "neutral insulin" (not glargine), 16 U/kg twice daily (T1 model) or 12 U/kg twice daily (T2 model), upregulated hepcidin expression and reversed the elevated intestinal iron absorption, serum iron, and hepatic iron seen in untreated diabetic rats (Wang H et al., Diabetes 2014;63(5):1506, PMID 24379355). [9] A separate theoretical paper proposes insulin/IGF-1 signaling raises HIF-1α activity, which independently regulates both erythropoiesis and intestinal iron absorption (McCarty MF, Medical Hypotheses 2003;61(5-6):567–573). [10]

Mechanism

Named for the rat/cell data: insulin receptor signaling through STAT3 (and partly ERK, independent of PI3K) directly upregulates hepatic hepcidin transcription and protein. [9] The HIF-1α pathway is theoretical only. [10]

Counter-evidence held on record

This is a reverse-direction, protective-hypothesis finding. No iron supplementation or restriction is implied for glargine users by this evidence.

Limits on what this shows

• Why no grade: Dual condition met. (1) No Tier B or Tier C evidence was located linking insulin glargine, or insulin as a class, to altered copper status; the only copper/insulin literature located concerns copper's effect on insulin secretion or resistance, the reverse direction, which does not support a drug-depletes-nutrient entry. (2) No circulating consumer claim that insulin depletes copper was identified during this review.
• Tooling limitation: This session's WebSearch tool query budget was exhausted partway through this review, which limited the range of additional phrasings that could be tried for copper specifically. A revision should re-run further phrasings against PubMed, Europe PMC, and Semantic Scholar before treating this gap as final.

Search effort disclosed

A targeted Crossref API bibliographic search ("exogenous insulin therapy serum copper status diabetes") returned five results, none addressing insulin's effect on copper (all concerned insulin dosing, antibody syndromes, or protein binding). [14]

Limits on what this shows

• Why no grade: Dual condition met. (1) No Tier B or Tier C evidence specific to exogenous insulin, or insulin glargine, altering gut microbiome composition was located; the diabetes-microbiome literature surfaced during this review concentrated on GLP-1 receptor agonists and metformin, not insulin. (2) No circulating consumer claim that insulin glargine disrupts the gut microbiome was identified.
• Tooling limitation: Attempts to directly query the Europe PMC REST API and PubMed for "insulin therapy" plus "gut microbiota" were blocked by persistent rate-limiting and bot-verification pages during this review, after the WebSearch tool's session budget had also been exhausted. This category's search was therefore narrower than the multi-phrasing, multi-host standard this protocol otherwise applies, and this gap should be re-checked in a future revision with fresh tooling access rather than treated as settled evidence of no effect.

Limits on what this shows

• Key negative/null findings: None located; this hypothesis has not been experimentally confirmed or refuted in the sources reviewed.
• At-risk subgroups: None established.
• Counter-evidence: This is a 2003 hypothesis article, not a study with a cohort. Per this protocol's rule against filing a drug's own hemodynamic mechanism as a deficiency, there is not even confirmed evidence of a real effect here, only a proposed mechanism that has not been tested.

Regulatory status

Not addressed in labeling; no hemoglobin/hematocrit warning appears in the LANTUS label as reviewed. [1]

Population evidence

None at Tier A or B. The only source located is a narrative hypothesis paper (McCarty MF, Medical Hypotheses 2003;61(5-6):567–573), proposing that insulin and IGF-1 raise HIF-1α activity, which in turn stimulates erythropoietin synthesis and intestinal iron uptake, offered as an explanation for the epidemiological association between insulin resistance and higher red-cell counts/iron stores. [10]

Mechanism

Theoretical only, as stated by the source itself; not tested empirically for insulin glargine or any specific insulin formulation. [10]

Counter-evidence held on record

Purely theoretical. Must not be presented to consumers as an established effect of insulin glargine on oxygen delivery in either direction.

Limits on what this shows

• Key negative/null findings: None in this source.
• At-risk subgroups: None identified.
• Counter-evidence: Same limitation as the Mitochondrial burden entry: standard insulin (not glargine), in vitro only, a single 20-minute acute exposure, not chronic subcutaneous dosing.

Regulatory status

Not addressed in labeling.

Population evidence

Same source as the Mitochondrial burden entry above (Nisr & Affourtit, 2014): coupling efficiency, the ATP-linked share of total oxygen consumption, increased significantly with insulin exposure in both rat and human muscle-cell models. [11]

Mechanism

Named. Decreased mitochondrial proton leak shifts a larger share of respiration toward ATP-synthase-coupled ATP production. [11]

Counter-evidence held on record

This entry shares its entire evidentiary basis with Mitochondrial burden above (see Overlap map); it is a protective signal, not a basis for energy-support supplementation claims.